BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17523986)

  • 1. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users.
    Wood E; Tyndall MW; Zhang R; Montaner JS; Kerr T
    Addiction; 2007 Jun; 102(6):916-9. PubMed ID: 17523986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employment among users of a medically supervised safer injection facility.
    Richardson L; Wood E; Zhang R; Montaner J; Tyndall M; Kerr T
    Am J Drug Alcohol Abuse; 2008; 34(5):519-25. PubMed ID: 18821450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility.
    Wood RA; Wood E; Lai C; Tyndall MW; Montaner JS; Kerr T
    Int J Drug Policy; 2008 Jun; 19(3):183-8. PubMed ID: 18367389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection drug users' perceptions regarding use of a medically supervised safer injecting facility.
    Petrar S; Kerr T; Tyndall MW; Zhang R; Montaner JS; Wood E
    Addict Behav; 2007 May; 32(5):1088-93. PubMed ID: 16930849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility.
    Milloy MJ; Kerr T; Mathias R; Zhang R; Montaner JS; Tyndall M; Wood E
    Am J Drug Alcohol Abuse; 2008; 34(4):499-509. PubMed ID: 18584579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do supervised injecting facilities attract higher-risk injection drug users?
    Wood E; Tyndall MW; Li K; Lloyd-Smith E; Small W; Montaner JS; Kerr T
    Am J Prev Med; 2005 Aug; 29(2):126-30. PubMed ID: 16005809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of on-site detoxification services co-located with a supervised injection facility.
    Gaddis A; Kennedy MC; Nosova E; Milloy MJ; Hayashi K; Wood E; Kerr T
    J Subst Abuse Treat; 2017 Nov; 82():1-6. PubMed ID: 29021106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with public injecting among users of Vancouver's supervised injection facility.
    McKnight I; Maas B; Wood E; Tyndall MW; Small W; Lai C; Montaner JS; Kerr T
    Am J Drug Alcohol Abuse; 2007; 33(2):319-25. PubMed ID: 17497555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility.
    Kerr T; Small W; Moore D; Wood E
    Int J Drug Policy; 2007 Jan; 18(1):37-45. PubMed ID: 17689342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to health and social services for IDU: the impact of a medically supervised injection facility.
    Small W; Van Borek N; Fairbairn N; Wood E; Kerr T
    Drug Alcohol Rev; 2009 Jul; 28(4):341-6. PubMed ID: 19594786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility.
    Wood E; Kerr T; Stoltz J; Qui Z; Zhang R; Montaner JS; Tyndall MW
    Public Health; 2005 Dec; 119(12):1111-5. PubMed ID: 16214189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of methadone use among Aboriginal opioid injection drug users.
    Wood E; Montaner JS; Li K; Barney L; Tyndall MW; Kerr T
    CMAJ; 2007 Jul; 177(1):37-40. PubMed ID: 17606937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Condom use among injection drug users accessing a supervised injecting facility.
    Marshall BD; Wood E; Zhang R; Tyndall MW; Montaner JS; Kerr T
    Sex Transm Infect; 2009 Apr; 85(2):121-6. PubMed ID: 18812391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility.
    Tyndall MW; Kerr T; Zhang R; King E; Montaner JG; Wood E
    Drug Alcohol Depend; 2006 Jul; 83(3):193-8. PubMed ID: 16356659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia.
    Salmon AM; van Beek I; Amin J; Kaldor J; Maher L
    Addiction; 2010 Apr; 105(4):676-83. PubMed ID: 20148794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime.
    Wood E; Tyndall MW; Lai C; Montaner JS; Kerr T
    Subst Abuse Treat Prev Policy; 2006 May; 1():13. PubMed ID: 16722550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seeking refuge from violence in street-based drug scenes: women's experiences in North America's first supervised injection facility.
    Fairbairn N; Small W; Shannon K; Wood E; Kerr T
    Soc Sci Med; 2008 Sep; 67(5):817-23. PubMed ID: 18562065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of methadone treatment on incarceration rates among injection drug users.
    Werb D; Kerr T; Marsh D; Li K; Montaner J; Wood E
    Eur Addict Res; 2008; 14(3):143-9. PubMed ID: 18552490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug injecting in patients in New Zealand Methadone Maintenance Treatment programs: an anonymous survey.
    Judson G; Bird R; O'Connor P; Bevin T; Loan R; Schroder M; McGrath R; Weatherall M; Moriarty H; Robinson G
    Drug Alcohol Rev; 2010 Jan; 29(1):41-6. PubMed ID: 20078681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
    Banta-Green CJ; Maynard C; Koepsell TD; Wells EA; Donovan DM
    Addiction; 2009 May; 104(5):775-83. PubMed ID: 19344438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.